12:00 AM
 | 
Sep 17, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

PX-866: Phase II expanded

Oncothyreon said it expanded an open-label, Canadian Phase II trial evaluating once-daily 8 mg oral PX-866 in about 40 patients who received no prior therapy to include a second part in an additional 25 patients who have progressed while receiving Zytiga...

Read the full 193 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >